Citations

Showing 10 of 108094 citations.

Outcomes after repeat hepatectomy for colorectal liver metastases from the colorectal liver operative metastasis international collaborative (COLOMIC)
Valenzuela, Cristian D. , Moaven, Omeed , Gawdi, Rohin , Piccolo, Nico R. Del, Cheung, Tan To, Corvera, Carlos U. , Wisneski, Andrew D. , Zarandi, Nima Pourhabibi , Dourado, Justin , Perry, Kathleen C., Shen, Perry , Del Piccolo, Nico R, Moaven, Omeed , Stauffer, John , Cheung, Tan To, Cha, Charles , Russell, Gregory B.

Mayo Clinic

Journal of Surgical Oncology | August 15, 2022 | Volume: 126 | Issue: 7 | Pages: 1242-1252

10.1002/jso.27056 | PMID 35969175 Get It

AbstractBackgroundResection of colorectal liver metastasis (CLM) is beneficial when feasible. However, the benefit of second hepatectomy for hepatic recurrence in CLM remains unclear.MethodsThe Colorectal Liver Operative Metastasis International Collaborative retrospectively examined 1004 CLM cases from 2000 to 2018 from a total of 953 patients. Hepatic recurrence after initial hepatectomy was identified in 218 patients. Kaplan–Meier analysis was performed for overall survival (OS) and recurrence‐free survival (RFS). Propensity score matching (PSM) was performed to offset selection bias. Cox proportional‐hazards regression was performed to identify risk factors associated with OS.ResultsA total of 51 patients underwent second hepatectomy. Unadjusted median OS was 60.1 months in repeat‐hepatectomy versus 38.3 months in the single‐hepatectomy group (p = 0.015). In the PSM population, median OS remained significantly better in the repeat‐hepatectomy group (60.1 vs. 33.1 months; p = 0.0023); median RFS was 12.4 months for the repeat‐hepatectomy group, versus 9.8 months in the single‐hepatectomy group (p = 0.0050). Repeat hepatectomy was associated with lower risk of death (hazard ratio: 0.283; p = 0.000012). Obesity, tobacco use, and high intraoperative blood loss were associated with significant risk of death (p < 0.05).ConclusionIn CLM with hepatic recurrence, second hepatectomy was beneficial for OS. With PSM, the OS benefit of performing a second hepatectomy remained significant.
Correction to: Complications and re‑operations after extensor mechanism repair surgery in a large cross‑sectional cohort: females and tobacco‑users at highest risk for adverse outcomes
Oeding, Jacob F. , Alrabaa, Rami George , Benjamin, C. , Oeding, Jacob F , Wong, Stephanie E. , Zhang, Alan L. , Feeley, Brian T. , Benjamin, C. , Lansdown, Drew Anderson

Mayo Clinic

Knee Surgery, Sports Traumatology, Arthroscopy | August 15, 2022 | Volume: 31 | Issue: 2 | Pages: 464-464

10.1007/s00167-022-07114-z | PMID 35970948 Get It

Cost-Effectiveness of Catheter Ablation Versus Antiarrhythmic Drug Therapy in Atrial Fibrillation: The CABANA Randomized Clinical Trial
Chew, Derek S. , Li, Yanhong , Cowper, Patricia A., Anstrom, Kevin J. , Piccini, Jonathan P. , Poole, Jeanne E. , Monahan, Kristi H. , Davidson‐Ray, Linda , Bahnson, Tristram D. , Al‐Khalidi, Hussein R. , Lee, Kerry L. , Packer, Douglas L. , Investigators, for the CABANA, Li, Yanhong , Monahan, Kristi H , Bahnson, Tristram D , Al-Khalidi, Hussein R , Packer, Douglas L , Mark, Daniel B , Daniels, Melanie R. , Mark, Daniel B. , Investigators, for the CABANA

Mayo Clinic

Circulation | August 15, 2022 | Volume: 146 | Issue: 7 | Pages: 535-547

10.1161/circulationaha.122.058575 | PMID 35726631 Get It

Background: In the CABANA trial (Catheter Ablation vs Antiarrhythmic Drug Therapy for Atrial Fibrillation), catheter ablation did not significantly reduce the primary end point of death, disabling stroke, serious bleeding, or cardiac arrest compared with drug therapy by intention-to-treat, but did improve the quality of life and freedom from atrial fibrillation recurrence. In the heart failure subgroup, ablation improved both survival and quality of life. Cost-effectiveness was a prespecified CABANA secondary end point. Methods: Medical resource use data were collected for all CABANA patients (N=2204). Costs for hospital-based care were assigned using prospectively collected bills from US patients (n=1171); physician and medication costs were assigned using the Medicare Fee Schedule and National Average Drug Acquisition Costs, respectively. Extrapolated life expectancies were estimated using age-based survival models. Quality-of-life adjustments were based on EQ-5D–based utilities measured during the trial. The primary outcome was the incremental cost-effectiveness ratio, comparing ablation with drug therapy on the basis of intention-to-treat, and assessed from the US health care sector perspective. Results: Costs in the first 3 months averaged $20 794±SD 1069 higher with ablation compared with drug therapy. The cumulative within-trial 5-year cost difference was $19 245 (95% CI, $11 360–$27 170) and the lifetime mean cost difference was $15 516 (95% CI, –$2963 to $35,512) higher with ablation than with drug therapy. The drug therapy arm accrued an average of 12.5 life-years (LYs) and 10.7 quality-adjusted life-years (QALYs). For the ablation arm, the corresponding estimates were 12.6 LYs and 11.0 QALYs. The incremental cost-effectiveness ratio was $57 893 per QALY gained, with 75% of bootstrap replications yielding an incremental cost-effectiveness ratio < $100 000 per QALY gained. With no quality-of-life/utility adjustments, the incremental cost-effectiveness ratio was $183 318 per LY gained. Conclusions: Catheter ablation of atrial fibrillation was economically attractive compared with drug therapy in the CABANA Trial overall at present benchmarks for health care value in the United States on the basis of projected incremental QALYs but not LYs alone.
Development and acceptability of a mobile health application integrated with the electronic heath record for treatment of chronic insomnia disorder
Anderson, Sandra E., Wahl, Adam , Clark, Patrick, Smith, J.M. , Luedke, Tabitha C., McColley, Samantha , Phillips, Sarah A. , Harper, Sarah B , Boudreau, Nancy B., Monson, Amanda J., Morgenthaler, Timothy I. , Kolla, Bhanu Prakash , Smith, Justin M, Smith, Justin , Luedke, Tabitha Crystal

Mayo Clinic

Journal of Clinical Sleep Medicine | August 15, 2022 | Volume: 18 | Issue: 12 | Pages: 2785-2792

10.5664/jcsm.10218 | PMID 35959953 Get It

Outcomes of Solid Organ Transplant Recipients Treated With Antispike Monoclonal Antibodies for Coronavirus Disease 2019 Across Variant Epochs: Impact of Comorbidities and Vaccination
Seville, Maria Teresa , Speicher, Leigh L. , Yetmar, Zachary A. , O’Horo, John C. , Ganesh, Ravindra , Razonable, Raymund R.

Mayo Clinic

Transplantation | August 15, 2022 | Volume: 106 | Issue: 11 | Pages: e507-e509

10.1097/tp.0000000000004325 | PMID 35969000 Get It

Proteomic Identification and Clinicopathologic Characterization of Splenic Amyloidosis
Chiu, April , Dasari, Surendra , Kurtin, Paul J. , Theis, Jason D. , Vrana, Julie A., Dao, Linda N. , Howard, Matthew T., Dalland, Joanna , Chiu, April , Rech, Karen L. , McPhail, Ellen Darcy

Mayo Clinic

American Journal of Surgical Pathology | August 15, 2022 | Volume: 47 | Issue: 1 | Pages: 74-80

10.1097/pas.0000000000001948 | PMID 35968972 Get It

The spleen is a commonly encountered specimen in surgical pathology. However, little is known about the incidence, morphologic pattern, and clinical features of spleens involved by amyloidosis. We retrospectively identified 69 spleen amyloid cases typed using a proteomics-based method between 2008 and 2020. The frequency of amyloid types, clinicopathologic features, and distribution of amyloid deposits were assessed. Four amyloid types were detected: immunoglobulin light chain (AL) (N=30; 43.5%); leukocyte chemotactic factor 2 amyloidosis (ALECT2) (N=30; 43.5%); amyloid A (AA) (N=8; 11.6%); and fibrinogen alpha (AFib) (N=1; 1.4%). The splenic amyloid showed 5 distinct distribution patterns: (1) diffuse pattern, exhibited by most AL cases; (2) red pulp pattern, exhibited by most ALECT2 cases; (3) multinodular pattern, seen in subsets of AA and AL-kappa cases; (4) mass-forming pattern, seen in the AFib case; and (5) vascular only, seen in a subset of AA cases. Atraumatic splenic rupture was the most common reason for splenectomy in AL cases, while most ALECT2 spleens were removed incidentally during an unrelated abdominal surgery. Splenomegaly was significantly more common in AA spleens than in AL or ALECT2 spleens and was often the reason for splenectomy in this group. In conclusion, splenic amyloid may be underrecognized as it is often an incidental finding. Although, as expected, many of the spleens were involved by AL amyloidosis, ALECT2 emerged as another common spleen amyloid type. Although the spleen amyloid types exhibited characteristic distribution patterns, proteomics-based typing is warranted as some morphologic overlap still exists. Awareness of ALECT2 as a major spleen amyloid type is important for appropriate diagnostic workup and patient management.
Septin‐5 and ‐7‐IgGs: Neurologic, Serologic, and Pathophysiologic Characteristics
Hinson, Shannon R., Honorat, Josephe A., Grund, Ethan M. , Clarkson, Benjamin D. , Miske, Ramona , Scharf, Madeleine, Zivelonghi, Cecilia , Al‐Lozi, Muhammad, Bucelli, Robert C. , Cho, Tracey , Grell, Jacquelyn A., López‐Chiriboga, A. Sebastian , Levin, Marc S., Merati, Melody, Montalvo, Mayra , Pittock, Sean J. , Wilson, Michael R. , Howe, Charles L. , Budhram, Adrian , Grell, Jacquelyn, Lopez-Chiriboga, A Sebastian , Pittock, S J , Wilson, Michael R , McKeon, Andrew , Howe, Charles L , Cho, Tracey A , Choi, Ellie, Levin, Marc, McKeon, Andrew

Mayo Clinic

Annals of Neurology | August 15, 2022 | Volume: 92 | Issue: 6 | Pages: 1090-1101

10.1002/ana.26482 | PMID 36053822 Get It

Background and ObjectivesWe sought to determine clinical significance of neuronal septin autoimmunity and evaluate for potential IgG effects.MethodsSeptin‐IgGs were detected by indirect immunofluorescence assays (IFAs; mouse tissue and cell based) or Western blot. IgG binding to (and internalization of) extracellular septin epitopes were evaluated for by live rat hippocampal neuron assay. The impact of purified patient IgGs on murine cortical neuron function was determined by recording extracellular field potentials in a multielectrode array platform.ResultsSeptin‐IgGs were identified in 23 patients. All 8 patients with septin‐5‐IgG detected had cerebellar ataxia, and 7 had prominent eye movement disorders. One of 2 patients with co‐existing septin‐7‐IgG had additional psychiatric phenotype (apathy, emotional blunting, and poor insight). Fifteen patients had septin‐7 autoimmunity, without septin‐5‐IgG detected. Disorders included encephalopathy (11; 2 patients with accompanying myelopathy, and 2 were relapsing), myelopathy (3), and episodic ataxia (1). Psychiatric symptoms (≥1 of agitation, apathy, catatonia, disorganized thinking, and paranoia) were prominent in 6 of 11 patients with encephalopathic symptoms. Eight of 10 patients with data available (from 23 total) improved after immunotherapy, and a further 2 patients improved spontaneously. Staining of plasma membranes of live hippocampal neurons produced by patient IgGs (subclasses 1 and 2) colocalized with pre‐ and post‐synaptic markers. Decreased spiking and bursting behavior in mixed cultures of murine glutamatergic and GABAergic cortical neurons produced by patient IgGs were attributable to neither antigenic crosslinking and internalization nor complement activation.InterpretationSeptin‐IgGs are predictive of distinct treatment‐responsive autoimmune central nervous system (CNS) disorders. Live neuron binding and induced electrophysiologic effects by patient IgGs may support septin‐specific pathophysiology. ANN NEUROL 2022;92:1090–1101
Diabetic Ketoacidosis in Pregnancy: An Overview of Pathophysiology, Management, and Pregnancy Outcomes
Dhanasekaran, Maheswaran , Mohan, Sneha , Egan, Aoife M.

Mayo Clinic

EMJ Diabetes | August 15, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.33590/emjdiabet/10194487 Get It

Diabetic ketoacidosis (DKA) is an obstetrical emergency that is associated with an elevated risk of adverse pregnancy outcomes. This includes pregnancy loss in up to 1 in 3 cases. Due to the normal metabolic changes that occur during pregnancy, females who are pregnant are more vulnerable to DKA, and it can occur at lesser than expected degrees of hyperglycaemia. Presenting symptoms can be non-specific and include nausea and vomiting, fatigue, polydipsia, and polyuria. DKA may be the first presentation of previously undiagnosed diabetes. Therefore, high index of suspicion, along with prompt diagnosis and management, is essential. The cornerstones of management include intravenous insulin, intravenous fluids, and electrolyte replacement. Treatment generally follows the principles for DKA management outside of pregnancy, with some additional considerations. Close maternal and fetal monitoring is essential, and intensive care unit admission is typically required to adequately achieve this goal. In all situations, a thorough investigation should occur to address the underlying cause of the DKA and prevent further episodes. This review article outlines the potential etiopathogenesis, clinical presentation, and management of DKA in pregnancy.
GLI1-Rearranged Enteric Tumor
Jessurun, José , Orr, Christine, McNulty, Samantha N. , Hagen, Catherine E. , Alnajar, Hussein , Wilkes, David , Kudman, Sarah , Assaad, Majd Al, Dorsaint, Princesca , Ohara, Kentaro , He, Feng , Chiu, Kenrry, Yin, Yong , Xiang, Jenny , Qin, Lihui , Elemento, Olivier , Yantiss, Rhonda K. , Orr, Christine , Al Assaad, Majd, Hagen, Catherine E , Orr, Christine, Assaad, Majd Al , Sboner, Andrea , Graham, Rondell P. , Poizat, Flora , Mosquera, Juan Miguel

Mayo Clinic

American Journal of Surgical Pathology | August 15, 2022 | Volume: 47 | Issue: 1 | Pages: 65-73

10.1097/pas.0000000000001950 | PMID 35968961 Get It

GLI1 encodes a transcription factor that targets cell cycle regulators affecting stem cell proliferation. GLI1 gene fusions were initially described in pericytomas with a t[7;12] translocation and more recently in gastric plexiform fibromyxomas and gastroblastomas. This study describes the clinicopathologic, immunohistochemical, and molecular features of three intestinal-based neoplasms harboring GLI1 gene fusions. We studied three unique mesenchymal small bowel tumors. Paraffin embedded tumor tissues from these cases and 62 additional tumor samples that included a plexiform fibromyxoma were sequenced using a targeted RNAseq method to detect fusion events. The study patients included two women and one man who were 52, 80, and 22 years of age at the time of diagnosis. The tumors involved the submucosa and muscularis propria of the duodenum, jejunum, and ileum. All 3 tumors contained a proliferation of monotonous oval or spindle cells with scattered, somewhat dilated vessels. Two cases showed epithelioid structures such as glands, tubules, or nests. Immunohistochemical analysis revealed cytokeratin expression in the epithelioid components of both tumors displaying these features, and variable numbers of mesenchymal cells. Diffuse CD56 positivity was seen in the mesenchymal component of 2 tumors and desmin and smooth muscle actin staining in the other tumor. Immunostains for S-100 protein, DOG-1, and CD117 were negative in all cases. GLI1 fusions with different partner genes were detected in all tumors, and in the plexiform fibromyxoma, used as a control. Validation by fluorescence in situ hybridization was performed. None of the tumors have recurred or metastasize after surgery. We describe novel GLI1 fusions in 3 mesenchymal neoplasms of the small intestine, including 2 with biphenotypic features. Thus far, all cases have pursued indolent clinical courses. We propose the term “ GLI1 -rearranged enteric tumor” to encompass this group of unique neoplasms of the small intestine that harbor GLI1 gene fusions and expand the spectrum of gastrointestinal neoplasms with these alterations.
Optimum Differentiation of Frontotemporal Lobar Degeneration from Alzheimer Disease Achieved with Cross‐Sectional Tau Positron Emission Tomography
Josephs, Keith A. , Tosakulwong, Nirubol , Gatto, Rodolfo G. , Weigand, Stephen D. , Ali, Farwa , Graff‐Radford, Jonathan , Savica, Rodolfo , Schwarz, Christopher G. , Kantarci, Kejal , Fields, Julie A. , Reichard, Ross R., Petersen, Ronald C. , Lowe, Val J. , Whitwell, Jennifer L. , Graff-Radford, Jonathan , Savica, Rodolfo , Schwarz, Christopher G , Kantarci, Kejal , Dickson, Dennis W , Petersen, Ronald C , Whitwell, Jennifer , Whitwell, Jennifer L , Botha, Hugo , Machulda, Mary M. , Senjem, Matthew L. , Boeve, Bradley F. , Jones, David T. , Ramanan, Vijay K. , Dickson, Dennis W. , Jack, Clifford R.

Mayo Clinic

Annals of Neurology | August 15, 2022 | Volume: 92 | Issue: 6 | Pages: 1016-1029

10.1002/ana.26479 | PMID 36054427 Get It

ObjectiveThis study was undertaken to assess cross‐sectional and longitudinal [18F]‐flortaucipir positron emission tomography (PET) uptake in pathologically confirmed frontotemporal lobar degeneration (FTLD) and to compare FTLD to cases with high and low levels of Alzheimer disease (AD) neuropathologic changes (ADNC).MethodsOne hundred forty‐three participants who had completed at least one flortaucipir PET and had autopsy‐confirmed FTLD (n = 52) or high (n = 58) or low ADNC (n = 33) based on Braak neurofibrillary tangle stages 0–IV versus V–VI were included. Flortaucipir standard uptake value ratios (SUVRs) were calculated for 9 regions of interest (ROIs): an FTLD meta‐ROI, midbrain, globus pallidum, an AD meta‐ROI, entorhinal, inferior temporal, orbitofrontal, precentral, and medial parietal. Linear mixed effects models were used to compare mean baseline SUVRs and annual rate of change in SUVR by group. Sensitivity and specificity to distinguish FTLD from high and low ADNC were calculated.ResultsBaseline uptake in the FTLD meta‐ROI, midbrain, and globus pallidus was greater in FTLD than high and low ADNC. No region showed a greater rate of flortaucipir accumulation in FTLD. Baseline uptake in the AD‐related regions and orbitofrontal and precentral cortices was greater in high ADNC, and all showed greater rates of accumulation compared to FTLD. Baseline differences were superior to longitudinal rates in differentiating FTLD from high and low ADNC. A simple baseline metric of midbrain/inferior temporal ratio of flortaucipir uptake provided good to excellent differentiation between FTLD and high and low ADNC (sensitivities/specificities = 94%/95% and 71%/70%).InterpretationThere are cross‐sectional and longitudinal differences in flortaucipir uptake between FTLD and high and low ADNC. However, optimum differentiation between FTLD and ADNC was achieved with baseline uptake rather than longitudinal rates. ANN NEUROL 2022;92:1016–1029